Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582547 | 0.88 | LRRK2 (0.39) | LRRK2RETDYRK1A | |
| SCHEMBL31219432 | 0.88 | RET (0.33) | LRRK2RET | |
| SCHEMBL26108241 | 0.88 | LRRK2 (0.39) | LRRK2RETDYRK1A | |
| SCHEMBL26106829 | 0.87 | SOS1 (0.31) | — | |
| SCHEMBL26106237 | 0.85 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL30582602 | 0.85 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL30582601 | 0.85 | PIK3CD (0.40) | LRRK2RETDYRK1ACCNT1CDK9 | |
| SCHEMBL26105782 | 0.85 | PIK3CD (0.40) | LRRK2RETDYRK1ACCNT1CDK9 | |
| SCHEMBL26134176 | 0.84 | LRRK2 (0.32) | LRRK2RETCCNT1CDK9 | |
| SCHEMBL26107050 | 0.84 | LCK (0.40) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067484-A1 | CRYSTAL FORMS AND SALTS OF SPIROBICYCLIC COMPOUND | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| EP-4499616-A1 | SPIROBICYCLIC COMPOUNDS | Acerand Therapeutics (Hong Kong) Limited (HK) | 2025-02-05 | — | — | EP | disclosed |
| CN-119013260-A | Spirobicyclic compounds | 优领医药科技(香港)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024091370-A1 | 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023192502-A1 | SPIROBICYCLIC COMPOUNDS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2023-10-05 | — | — | WO | disclosed |